Site search

Clear filter
2901 results for '' found
Development of Clinical Utility for Point of Care MRI (Trial Not Registered)
Development of Clinical Utility for Point of Care MRI (Trial Not Registered)
/
PMR-116 in Patients with Advanced Malignancies (ACTRN12620001146987)
PMR-116 in Patients with Advanced Malignancies (ACTRN12620001146987)
/
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis
/
A Proof Of Concept study to evaluate the sensitivity and specificity of Wearables and Algorithm Technology for Chronic Heart Disease for improved diagnosis of Heart Failure (ACTRN12623000038695)
/
A prospective, randomized, single-blinded, sham controlled study of Pelvic Vein Embolization (PVE) for treatment of erectile dysfunction (ED) (ACTRN12620001023943)
A prospective, randomized, single-blinded, sham controlled study of Pelvic Vein Embolization (PVE) for treatment of erectile dysfunction (ED) (ACTRN12620001023943)
/
A Prospective angiOtensin vs. noRadrenaline Trial for Hypotension management to reduce length Of hospital stay in Cardiac Surgery (the PORTHOS study) (ACTRN12623000848606p)
A Prospective angiOtensin vs. noRadrenaline Trial for Hypotension management to reduce length Of hospital stay in Cardiac Surgery (the PORTHOS study) (ACTRN12623000848606p)
/
A phase 2 randomised, open-label trial of maintenance of weight loss with alternate-weekly incretin medication dosing (ACTRN12625000609459)
A phase 2 randomised, open-label trial of maintenance of weight loss with alternate-weekly incretin medication dosing (ACTRN12625000609459)
/
PFOX:  Pulmonary Fibrosis Ambulatory Oxygen Trial (NCT03737409)
PFOX: Pulmonary Fibrosis Ambulatory Oxygen Trial (NCT03737409)
/
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PLACEBOCONTROLLED MULTI-CENTER STUDY WITH A DOUBLE-BLIND 52-WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UP/DOSE DOWN TITRATION INVESTIGATING THE EFFICAC
/
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSE-UP TITRATION, MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY, EFFICACY, AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSE-UP TITRATION, MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY, EFFICACY, AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH
/
28 29 30 31 32